Skip to content

EV / EBITDA at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
12.3×-6.5×
Stryker logo
StrykerSYK
22.1×-11.8×
IAR
Integra LifeSciencesIART
19.7×+3.6×
Solventum logo
SolventumSOLV
6.4×-8.8×
Xtant Medical Holdings logo
Xtant Medical HoldingsXTNT
7.2×
Organogenesis Holdings Inc. logo
Organogenesis Holdings Inc.ORGO
13.6×

Other financials

Income statement

See full
Revenue$27.8M+18.6%
Gross profit$25.9M+19.8%
Operating income$2.6M+221%
Net income$459.0K+113%
EPS (diluted)$0.05+112%

Balance sheet

See full
Cash & equivalents$13.6M-34.3%
Total debt$48.4M+8.2%
Total equity$7.0M-80.8%
Total assets$69.3M-28.1%

Cash flow

See full
Operating cash flow-$2.5M-23.3%
CapEx$43.8K-97.5%
Free cash flow-$2.5M+32.6%

Valuation

See full
Market cap$216.18M-9.7%
Enterprise value$250.95M-6.5%
P/S-0.5×

Profitability

See full
Gross margin92.9%+1.8pp
Operating margin6.1%+5.1pp
Net margin-31.2%-93.4pp
FCF margin-9.8%-3.5pp

Returns & leverage

See full
Return on equity-153.7%-199pp
Debt / equity6.9×+5.7×
Current ratio2.3×-0.5×

Where this comes from

Calculated from Sanara MedTech Inc.’s reported figures.

Based on the most recent quarter.

The official record: Sanara MedTech Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sanara MedTech Inc.'s ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sanara MedTech Inc.'s EV / EBITDA?
Sanara MedTech Inc. (SMTI) reported EV / EBITDA of 19.2× in Q1 2026.
How has Sanara MedTech Inc.'s EV / EBITDA changed year-over-year?
Sanara MedTech Inc.'s EV / EBITDA decreased by 62.0% year-over-year, from 50.5× to 19.2×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.